New guidelines for the diagnosis and treatment of infections due to Aspergillus species were published in August of 2016 by the Infectious Diseases Society of America (IDSA) (1), replacing those previously published in 2008 (2) . These guidelines incorporate new data published between January 2008 and December 2014. The document provides guidance on non-culture-based diagnosis of Aspergillus infections, discourages the use of combination anti-fungal therapy for primary management, and begins to define the place in therapy for isavuconazole, a new anti-fungal drug of the azole class approved by the U.S. Food and Drug Administration (FDA) in March 2015 to treat aspergillosis and mucormycosis.
The guidelines address 98 clinical questions that cover the three main presentations of Aspergillus infection, invasive, chronic or "saprophytic", and allergic aspergillosis. The executive summary succinctly lists these 98 questions, while the body of the document elaborates the evidence base for each recommendation. The strength of and evidence basis for each recommendation is presented via a Grading of Recommendations, Assessment, Development and Evaluation (GRADE) score (1) . Table 1 lists selected key elements of the guideline along with the strength and quality of the evidence in support of each recommendation.
A central recommendation that remains unchanged from the previous iteration of the guidelines is the pre-eminence of voriconazole as first-line therapy for treatment of all invasive forms of aspergillosis. This recommendation has the greatest strength and highest level of evidence when applied to pulmonary aspergillosis, but is less robust when applied to other forms of aspergillosis. Routine use of combination anti-fungal therapy is not recommended for primary therapy [although the use of voriconazole and an echinocandin "can be considered in select patients" (graded as a weak recommendation with moderate-quality evidence)]. Liposomal amphotericin B is retained as an alternative option for primary treatment. For empiric or pre-emptive anti-fungal therapy (disease site unspecified), liposomal amphotericin B, caspofungin, micafungin, or voriconazole are recommended. Anidulafungin is not recommended since no published trials have examined its efficacy as monotherapy for aspergillosis. For prophylaxis of invasive disease in high-risk patients (defined as individuals with graft-versus-host disease or patients with acute myelogenous leukemia or myelodysplastic syndrome and neutropenia), posaconazole is recommended, either in the oral suspension form, as in the previous guideline version, or by extended-release tablet (new recommendation) (1, 2) . Patients treated for pulmonary aspergillosis in the past should receive secondary prophylaxis during future periods of immune suppression.
Modifications to the previous recommendations for management of aspergillosis include the addition of isavuconazole as an alternative to voriconazole for primary
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Updated guidelines for the diagnosis and management of aspergillosis There are few revisions to the guidelines for non-invasive forms of aspergillosis, a category that includes aspergilloma, chronic cavitary pulmonary aspergillosis (CCPA), allergic bronchopulmonary aspergillosis (ABPA), and allergic Aspergillus sinusitis. One modification is that treatment for CCPA is now identical to that for IPA. For allergic rhinosinusitis, the recommendation for polypectomy, sinus washout, and intranasal steroids as a combined primary approach is also new.
For the first time, the guidelines advise reducing mold exposure within the hospital or home environment for the most vulnerable patient groups. Populations at highest risk include persons undergoing allogeneic hematopoietic stem cell transplant (HSCT) or receiving induction chemotherapy for acute leukemia. These highly immunecompromised patients should be placed in enclosed areas engineered to reduce mold exposure, where feasible. Appropriate methods for protection include high-efficiency particulate air filtration, laminar airflow, positive pressure rooms, and a standardized number of air exchanges per hour. Alternatively, in facilities without sophisticated engineering barriers, the guidelines advise using private rooms without conduits to construction sites, and avoiding exposure to plants, soil, or cut flowers. High-risk outpatients should avoid gardening, mulching, and proximity to construction sites or renovations. Cancer and transplant centers should perform surveillance for aspergillosis, to identify trends in the incidence of invasive fungal infections and allow early detection of new outbreaks.
Enthusiasm for biologic therapies, such as granulocyte infusions, granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat invasive aspergillosis remains low (treatment can be considered in patients with refractory neutropenia and aspergillosis), due to unestablished efficacy in human fungal infection. G-CSF and GM-CSF have not been tested in clinical trials of aspergillosis or other infections, although they are effective in shortening the duration of neutropenia. Recently, macrophage colony-stimulating factor (M-CSF) was shown to be protective against otherwise lethal Aspergillus infection in a mouse model of hematopoietic stem/progenitor cell transplant, in contrast to G-CSF, which had no effect on survival (3) .
Three other areas of expanded discussion in the new guidelines include (I) non-culture-based diagnosis of aspergillosis through measurement of fungal cell wall components [1,3-β-D-glucan (DG) and galactomannan (GM)] or amplification of Aspergillus by polymerase chain reaction (PCR) in host tissues; (II) testing for resistance; and (III) the role of combination anti-fungal therapy.
Methods for the laboratory diagnosis of aspergillosis have evolved considerably beyond culture and now involve detection of fungal cell wall components in human tissues, particularly within blood and bronchoalveolar lavage fluid (BALf), and amplification of fungal DNA by PCR. It is well known but worth restating that yields from fungal culture can be quite low: only 25-52% of Aspergillus infections are diagnosed based on growth in culture (4, 5) . Thus, it is not surprising that nearly 45% of cases reported in one large case series (4) met criteria for "probable", rather than "proven", disease (6) . Nonetheless, researchers and clinicians treat these two categories of patients identically. The guidelines intend for the term "invasive aspergillosis" to apply to probable as well as proven cases, but end up placing disproportionate emphasis on culture-based methods of diagnosis: " (1) .
Clinicians in practice treat many patients in the latter category, for whom the diagnosis of aspergillosis has been made in the appropriate clinical (host) context, on the basis of elevated serum or BALf fungal markers in combination with abnormal chest or other imaging. The guidelines recommend restricting the use of either GM or DG as nonculture-based diagnostic tools in patients with hematologic malignancy or HSCT. The lower sensitivity and specificity of these assays outside these high-risk groups, for example, in solid organ transplant recipients, is well supported by the literature (7) (8) (9) (10) (11) . Consequently, the use of GM or DG as a tool for the diagnosis of aspergillosis in patients with organ transplantation or chronic granulomatous disease (CGD) is discouraged by the guideline authors. The combined or sequential use of these biomarkers, with or without PCR, to diagnosis invasive aspergillosis is not addressed.
The guidelines stop short of recommending Aspergillus PCR of blood or BALf to aid diagnosis or decisions regarding preemptive anti-fungal therapy, given the lack of standardization of PCR targets and protocols and absence of studies showing clinical utility. Nonetheless, clinicians in the United States are likely to include PCR assays in their diagnostic repertoire, since DNA detection can exceed culture in sensitivity, PCR of blood or BAL specimens has a relatively high negative predictive value for invasive aspergillosis (12) , and its lower specificity may be offset when combined with GM. In addition, new PCR assays have the ability to detect specific strains of Aspergillus and common azole-resistance mutations in the Cyp51A gene (13) . The combination of GM and PCR may be particularly useful for earlier diagnosis of invasive aspergillosis (14, 15) .
Evidence suggests that there is increasing resistance to azoles among Aspergillus species in centers outside the United States (16) (17) (18) . Estimates of mortality attributable to azole-resistant aspergillosis range as high as 88% (19) . Despite this trend, the guidelines, somewhat surprisingly, recommend against resistance testing during primary diagnosis and treatment of aspergillosis. This reluctance arises mostly from technical considerations-the lack of clinically established susceptibility breakpoints for moldsrather than a prediction that Aspergillus resistance is unlikely to appear in the U.S. Information on Aspergillus resistance patterns in the U.S. is scant, and this gap in the literature should be addressed. Combination anti-fungal therapy is also discouraged by the guideline authors, due to contradictory results from small studies of combination therapy and little concern to date regarding the emergence of resistance. Results from one large study of combination therapy using anidulafungin and voriconazole for pulmonary aspergillosis were inconclusive, but showed benefit in a post-hoc analysis of a subgroup of patients diagnosed by positive galactomannan and radiographic findings (20) .
In summary, in the most recent U.S. guidelines for aspergillosis, voriconazole remains first-line treatment for most forms of the disease. Isavuconazole, a promising drug approved in 2015 for treatment of aspergillosis and mucormycosis, is accorded a limited place in therapy as an alternative to voriconazole. Resistance testing and combination anti-fungal therapy are discouraged in initial management, but may be considered for patients failing treatment. The fungal biomarkers GM and DG are useful diagnostic tools in high-risk groups. PCR is a promising new diagnostic tool, but lack of standardization, commercial assays in the U.S., and proof of clinical utility limit its broad dissemination.
